home  |  clinical trials Clinical Trials
M. D. Anderson conducts one of the world's largest clinical trials programs, offering more than 1,000 clinical trials – the most available anywhere – including treatment, prevention, diagnosis, survivorship and quality of life. Many of these studies are only offered here.

Find out if your patients are eligible / collaborate on research. In the Office of Physician Relations, we help identify the appropriate research staff to discuss clinical trials and eligibility criteria specific for your patient.
 

Contact Our Office for Assistance

  • FAX the completed Clinical Trial Information Request Form to (713) 794-4685
  • Phone our office for assistance at (713) 792-6161 or (800) 392-1611
  • E-mail us at physicianrelations@mdanderson.org
We will contact you within 48 hours (excluding weekends and holidays) with the status of your request.

Download a Clinical Trials Request Form
View Studies By:

Cancer Type | Treatment | Study Number | Physician | Phase | Clinical Trials Registration Number (NCT#)

About Clinical Trials

What Are They? | The Phases of Clinical Trials | Participating in Clinical Trials | Frequently Asked Questions



Clinical Trial Videos/Podcasts

New Treatment for Early Stage Lung Cancer (4:29)



Clinical Trial Lists

Melanoma Clinical Trials (PDF Format)
Neuro-Oncology Clinical Trials (PDF Format)
Genitourinary Clinical Trials (PDF Format)
Endocrine Clinical Trials (PDF Format)
Colon and Colorectal Cancer Clinical Trials (PDF Format)
Thoracic & Cardiovascular Surgery Clinical Trials (mdanderson.org)
Leukemia Clinical Trials (mdanderson.org)
New Options for Patients with Hodgkin Lymphoma (PDF Format)
New Options for Patients with T- Cell Lymphoma (PDF Format)
Trials Available at MD Anderson Regional Care Centers



Individual Clinical Trials

Genitourinary Protocol #2009-0378: Intermittent Androgen Deprivation Therapy plus Ipilumimab (Yervoy) for Men with Metastatic Hormone Sensitive Prostate Cancer. A Phase II Study of Ipilimumab plus Androgen Deprivation Therapy in Castrate Sensitive Prostate Carcinoma

BATTLE-2 Program Protocol #2009-0360:
A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer

Lymphoma/Myeloma Protocol #2010-0837:
A Multicenter Trial Available for Relapsed or Refractory Mantle Cell Lymphoma (MCL)

Lymphoma Protocol #2010-0776: Promising Frontline Treatment Option for Patients with Anaplastic Large Cell Lymphoma (ALCL)

Lymphoma Protocol #2010-0776: Promising Frontline Treatment Option for Patients with Anaplastic Large Cell Lymphoma (ALCL)

Thoracic Protocol #2006-0340: A Study Available for Stage I Non-Small Cell Lung Cancer (NSLC)

Behavioral Science Protocol #2006-0340: A New Program Available for Women With Sexual Problems After Cancer

Leukemia Protocol #2010-0123: A Phase II Trial of Eltrombopag for Patients with Chronic Lymphocytic Leukemia (CLL) and Thrombocytopenia

Melanoma Protocol #2010-0113: A Phase II Trial of High Dose Interleukin-2 with Recombinant MAGE-A3 Protein Combined with Adjuvant System AS15 in Patients with Unresectable or Metastatic Melanoma

Melanoma Protocol #2005-0143: Neoadjuvant Treatment for Resectable Metastatic Melanoma

Melanoma Protocol #2007-0450: Treatment with Decitabine and Peg-Interferon for Advanced Melanoma

Leukemia Protocol #2009-0546: A Phase I/II Clinical Trial of Fludarabine, Bendamustine, and Rituximab (FBR) in Previously Treated Patients with Chronic Lymphocytic Leukemia (CLL)

Neuro-Oncology Protocol #2009-0597: A Randomized Phase II Trial of Standard Dose Bevacizumab versus Low Dose Bevacizumab plus Lomustine (CCNU) In Adults with Recurrent Glioblastoma

Leukemia Protocol #2004-0144: A Phase I Study of 8-Chloro-Adenosine in Previously Treated Patients with Chronic Lymphocytic Leukemia

Melanoma Protocol #2010-0350: A Selective BRAF Inhibitor Available for Previously Treated BRAF Mutant Metastatic Melanoma

Melanoma Protocol #2008-0416: Vaccine Therapy for Patients with Metastatic Melanoma

Pediatric Protocol #2006-0752: Haploidentical Natural Killer (NK)Cells for Relapsed or Refractory Neuroblastoma

Stem Cell Transplantation Protocol #2009-0266: Haploidentical Stem Cell Transplantation for Patients without a Matched Sibling or Unrelated Donor